Atypical Hemolytic Uremic Syndrome: Crovalimab for Kids

We are studying the safety and effectiveness of crovalimab in children with atypical hemolytic uremic syndrome. This trial includes both new patients and those switching from other treatments.

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Crovalimab
Crovalimab is a lab-made antibody that blocks part of the immune system to stop abnormal red blood cell destruction in paroxysmal nocturnal hemoglobinuria.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
UZ Leuven
Nephrology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Pedatric Nephrology/Rheumatology
Ledeberg, Belgium
CHC MontLegia
Pediatrics
Liège, Belgium

Sponsor: F. Hoffmann-La Roche AG
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.